Asthma Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Asthma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Asthma Pipeline Report
• DelveInsight's Asthma pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for Asthma treatment.
• The leading companies working in the Asthma Market include Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, and others.
• Promising Asthma Pipeline Therapies in the various stages of development include DUPIXENT®, Tezepelumab, MEDI9929, Revamilast, Benralizumab, AZD7594, GSK3511294 (Depemokimab), and others.
• April 2024: AstraZeneca- A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants With Severe Asthma Including Several Under-Studied Populations in the United States (PASSAGE).
• March 2024: Bond Avillion 2 Development LP- A Multicenter, Randomized, Double-blind, Parallel-group, Event-driven, Decentralized, Phase IIIb Study Comparing PT027 With PT007 Administered as Needed in Participants 12 Years of Age and Older With Asthma (BATURA).

Request a sample and discover the recent advances in Asthma Treatment Drugs @ Asthma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Asthma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Asthma Overview
Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen.

Find out more about Asthma Treatment Landscape @ Drugs for Asthma Treatment- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Asthma Emerging Drugs Profile
• Dexpramipexole: Areteia Therapeutics
• TQC2731: Chia Tai Tianqing Pharmaceutical Group
• SHR-1703: Jiangsu HengRui Medicine

Asthma Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the Asthma therapies. The Asthma Companies which have their Asthma drug candidates in the most advanced stage, i.e. phase III include, Areteia Therapeutics.

DelveInsight's Asthma pipeline report covers around 100+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Asthma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Asthma Pipeline Therapies @ Asthma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Asthma Pipeline Report
• Coverage- Global
• Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Asthma Companies- Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, and others.
• Asthma Pipeline Therapies- DUPIXENT®, Tezepelumab, MEDI9929, Revamilast, Benralizumab, AZD7594, GSK3511294 (Depemokimab), and others.

Dive deep into rich insights for new drugs for Asthma Treatment, Visit @ Asthma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Asthma Executive Summary
3. Asthma: Overview
4. Asthma Pipeline Therapeutics
5. Asthma Pipeline Therapeutic Assessment
6. Asthma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. PT-027: Avillion LLP
9. Mid Stage Products (Phase II/III)
10. PT001: Pearl Therapeutics (AstraZeneca)
11. Mid Stage Products (Phase II)
12. FP 025: Foresee Pharmaceuticals
13. Early Stage Products (Phase I/II)
14. AQ-001S: Aquilon Pharmaceuticals S.A
15. Early Stage Products (Phase I)
16. Itolizumab (EQ001): Equillium
17. Preclinical and Discovery Stage Products
18. KBP7026: KBP Biosciences
19. Inactive Products
20. Asthma Key Companies
21. Asthma Key Products
22. Asthma- Unmet Needs
23. Asthma- Market Drivers and Barriers
24. Asthma- Future Perspectives and Conclusion
25. Asthma Analyst Views
26. Asthma Key Companies
27. Appendix

For further information on the Asthma Pipeline Therapeutics, reach out @ Asthma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.